JP2008521795A5 - - Google Patents

Download PDF

Info

Publication number
JP2008521795A5
JP2008521795A5 JP2007542513A JP2007542513A JP2008521795A5 JP 2008521795 A5 JP2008521795 A5 JP 2008521795A5 JP 2007542513 A JP2007542513 A JP 2007542513A JP 2007542513 A JP2007542513 A JP 2007542513A JP 2008521795 A5 JP2008521795 A5 JP 2008521795A5
Authority
JP
Japan
Prior art keywords
leptin
antagonist
seq
leptin antagonist
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007542513A
Other languages
English (en)
Japanese (ja)
Other versions
JP5113526B2 (ja
JP2008521795A (ja
Filing date
Publication date
Priority claimed from US10/996,607 external-priority patent/US7307142B2/en
Application filed filed Critical
Publication of JP2008521795A publication Critical patent/JP2008521795A/ja
Publication of JP2008521795A5 publication Critical patent/JP2008521795A5/ja
Application granted granted Critical
Publication of JP5113526B2 publication Critical patent/JP5113526B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007542513A 2004-11-26 2005-11-24 レプチン拮抗薬 Expired - Fee Related JP5113526B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/996,607 2004-11-26
US10/996,607 US7307142B2 (en) 2004-11-26 2004-11-26 Leptin antagonists
PCT/IL2005/001250 WO2006056987A2 (en) 2004-11-26 2005-11-24 Leptin antagonists

Publications (3)

Publication Number Publication Date
JP2008521795A JP2008521795A (ja) 2008-06-26
JP2008521795A5 true JP2008521795A5 (enExample) 2009-02-05
JP5113526B2 JP5113526B2 (ja) 2013-01-09

Family

ID=36204374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007542513A Expired - Fee Related JP5113526B2 (ja) 2004-11-26 2005-11-24 レプチン拮抗薬

Country Status (8)

Country Link
US (1) US7307142B2 (enExample)
EP (1) EP1814986B1 (enExample)
JP (1) JP5113526B2 (enExample)
CN (1) CN101189335B (enExample)
AT (1) ATE498683T1 (enExample)
DE (1) DE602005026432D1 (enExample)
ES (1) ES2363011T3 (enExample)
WO (1) WO2006056987A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
JP5622720B2 (ja) * 2008-05-21 2014-11-12 ニューロテスインコーポレイテッド 神経原繊維変化に関連する進行性認知障害の治療方法
CA2742600A1 (en) * 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
US8778890B2 (en) 2009-03-31 2014-07-15 Temple University—Of the Commonwealth System of Higher Education Leptin antagonist and methods of use
CN102958531A (zh) * 2010-04-22 2013-03-06 耶路撒冷希伯来大学伊森姆研究发展公司 高亲和力瘦蛋白和瘦蛋白拮抗剂
WO2014024189A1 (en) * 2012-08-06 2014-02-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pegylated high affinity leptins with increased biological activity
IT1423968B1 (enExample) * 2014-04-28 2016-08-26
US10926006B2 (en) 2015-02-26 2021-02-23 Remodeless Cv Ltd Drug eluting stent
US11123461B2 (en) 2015-02-26 2021-09-21 Remodeless Cv Ltd Treatment of ischemia and reperfusion using leptin antagonist
CA2977607A1 (en) * 2015-02-26 2016-09-01 Jacob Schneiderman Methods and compositions relating to leptin antagonists
CN104829708B (zh) * 2015-05-06 2017-11-28 广东省生物资源应用研究所 一条d螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
EA201991075A1 (ru) * 2016-11-08 2019-10-31 Антигенсвязывающие белки, которые проявляют антагонизм в отношении лептинового рецептора
LT3773713T (lt) 2018-04-06 2025-08-25 Regeneron Pharmaceuticals, Inc. Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija
MX2021007394A (es) 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
WO2024050285A2 (en) * 2022-08-31 2024-03-07 The Board Of Trustees Of The Leland Stanford Junior University Leptin analogs for treating obesity and weight management

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
US20020160935A1 (en) * 2000-03-24 2002-10-31 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
CA2266585A1 (en) * 1996-09-20 1998-03-26 Hoechst Aktiengesellschaft Use of leptin antagonists for treating insulin resistance in type ii diabetes
RU2003125638A (ru) * 2001-02-06 2005-03-10 Мерк Патент ГмбХ (DE) Модифицированный лептин с уменьшенной иммуногенностью

Similar Documents

Publication Publication Date Title
RU2016103067A (ru) Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей
JP2011511753A5 (enExample)
JP2009524429A5 (enExample)
HRP20161458T1 (hr) Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze
JP2013515055A5 (enExample)
NO20025153D0 (no) FremgangsmÕter og sammensetninger for Õ svekke formering av HIV-1
JP2013515057A5 (enExample)
JP2003501068A5 (enExample)
JP2014510518A5 (enExample)
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
JP2003515323A5 (enExample)
JP2010529860A5 (enExample)
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
JP2003533186A5 (enExample)
JP2009533317A5 (enExample)
JP2010513327A5 (enExample)
JP2025521082A5 (enExample)
WO2007018619A3 (en) Chimeric therapeutic agents
JP2006514820A5 (enExample)
WO2008113970A3 (en) Peptides
DE602004027362D1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
JP2012518669A5 (enExample)
JP2006514822A5 (enExample)
EP1982992A4 (en) HLA BINDING PEPTIDE, PRE-STEP, DNA DOMAGING AND RECOMBINANT VECTOR
JP2008510468A5 (enExample)